Stock Track | Ironwood Pharmaceuticals Plunges as Analysts Slash Revenue Estimates

Stock Track08-14

Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the pharmaceutical company.

According to the latest analyst coverage, the consensus revenue estimate for Ironwood Pharmaceuticals in 2024 has been slashed by 13% to $356 million, reflecting a notable 11% decline from its sales over the past 12 months. The analysts cited a weaker outlook for the company, signaling that investors should temper their expectations.

Furthermore, the consensus price target for Ironwood Pharmaceuticals has been cut by 21% to $12.50, indicating that analysts are less optimistic about the company's valuation following the downward revisions to revenue estimates. The analysts' forecasts imply that Ironwood Pharmaceuticals' revenue growth is expected to significantly underperform the wider industry, with an annualized revenue decline of 21% by the end of 2024, compared to an industry average growth of 23%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1129096758?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-14 23:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1129096758","market":"us","top_or_hot":-1,"title":"Stock Track | Ironwood Pharmaceuticals Plunges as Analysts Slash Revenue Estimates","media":"Stock Track","content":"<p>Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the pharmaceutical company.</p>\n\n<p>According to the latest analyst coverage, the consensus revenue estimate for Ironwood Pharmaceuticals in 2024 has been slashed by 13% to $356 million, reflecting a notable 11% decline from its sales over the past 12 months. The analysts cited a weaker outlook for the company, signaling that investors should temper their expectations.</p>\n\n<p>Furthermore, the consensus price target for Ironwood Pharmaceuticals has been cut by 21% to $12.50, indicating that analysts are less optimistic about the company's valuation following the downward revisions to revenue estimates. The analysts' forecasts imply that Ironwood Pharmaceuticals' revenue growth is expected to significantly underperform the wider industry, with an annualized revenue decline of 21% by the end of 2024, compared to an industry average growth of 23%.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Ironwood Pharmaceuticals Plunges as Analysts Slash Revenue Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Ironwood Pharmaceuticals Plunges as Analysts Slash Revenue Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n2024-08-14 23:18 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IRWD","symbol_name":"Ironwood医药","start_time":0,"source_url":"","article_id":"1129096758","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1129096758","pubTimestamp":1723648704,"sourceInfo":null,"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Ironwood Pharmaceuticals, Inc.  tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the pharmaceutical company.According to the latest analyst coverage, the consensus revenue estimate for Ironwood Pharmaceuticals in 2024 has been slashed by 13% to $356 million, reflecting a notable 11% decline from its sales over the past 12 months. The analysts cited a weaker outlook for the company, signaling that investo","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IRWD":"Ironwood医药"},"translate_title":"分析师大幅下调收入预期，铁木制药股价暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IRWD":1},"content_text":"Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) tumbled 5.01% during intraday trading on Wednesday, as analysts significantly lowered their revenue estimates and price targets for the pharmaceutical company.\nAccording to the latest analyst coverage, the consensus revenue estimate for Ironwood Pharmaceuticals in 2024 has been slashed by 13% to $356 million, reflecting a notable 11% decline from its sales over the past 12 months. The analysts cited a weaker outlook for the company, signaling that investors should temper their expectations.\nFurthermore, the consensus price target for Ironwood Pharmaceuticals has been cut by 21% to $12.50, indicating that analysts are less optimistic about the company's valuation following the downward revisions to revenue estimates. The analysts' forecasts imply that Ironwood Pharmaceuticals' revenue growth is expected to significantly underperform the wider industry, with an annualized revenue decline of 21% by the end of 2024, compared to an industry average growth of 23%.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1129096758"}